


### ORDERING INFORMATION

	Code	Composition
CHEMILAB	 B81180221	n° 2 vials x 34 mL (R.A) n° 1 vial x 12 mL (R.B)

### INTENDED USE


Product for use in the quantitative determination in vitro of Cholinesterase activity in human serum and plasma. The results of the test must always be interpreted in conjunction with the clinical context. FOR PROFESSIONAL USE ONLY.

### CLINICAL SIGNIFICANCE

The Cholinesterase enzyme is synthesized in the liver. It is present in the pancreas, myocardium and serum. Cholinesterase activity in the serum is the result of the activity of 13 isoenzymes. It is an index of liver function, although it is seen to be altered only in cases of very advanced hepatitis or cirrhosis. Other clinical situations in which an alteration in the cholinesterase concentration can be seen are poisoning by organic compounds (anticholinergic substances) and some forms of anemia. The activity of this enzyme is also determined before subjecting patients to treatment with muscle-relaxants containing succinylcholine.


### PRINCIPLE OF THE METHOD

Method Enzymatic (Butyrylthiocholine). Pseudocholinesterase (acylcholine acylhydrolase, EC 3.1.1.8) hydrolyses butyrylthiocholine to butyric acid and thiocholine which in turn reacts with DTNB. This reaction frees intensely yellow-coloured 5-thio-2-nitrobenzoic acid.



The rate at which the colour forms is directly proportional to the cholinesterase activity.

### Storage and stability

 = storage temperature 2 - 8°C

If stored closed at the indicated temperature, avoiding direct light, the intact reagents are stable until the expiration date, printed on the label.

### Concentrations

Reagent A:		
	Conc.	U.M.
Phosphate buffer pH 7.7 ± 0.2	50.5	mmol/L
5,5'-dithio-bis-2-nitrobenzoic acid	0.253	mmol/L
Reagent B:		
Butyrylthiocholine iodide substrate	30.3	mmol/L

### Reagents included in the kit

The reagent is described above.

### Materials required but not supplied in the kit

Controls, calibrators and pipettes with adequate volume.

### PRECAUTIONS and WARNINGS

1. Reagents and waste materials shall be disposed of in accordance with Community waste provisions or national or regional provisions.
2. Reagents may contain non-active components such as preservatives and detergents. The total concentration of these components is below the limits set out in Regulation 1272/2008 EC and subsequent amendments and additions.
3. It is recommended that the reagent be handled in accordance with the rules of good laboratory practice and that appropriate personal protective equipment be used.
4. Do not use the reagent if it is visibly degraded (e.g. presence of corpuscles).
5. All human samples shall be handled and disposed of as potentially infectious material.
6. The kit should only be used by qualified and properly trained technical personnel.
7. Diagnoses shall be carried out exclusively by authorised and qualified personnel.
8. Comply with national directives on occupational safety and quality assurance.
9. Use equipment that complies with current regulations.

### Reporting of serious incidents

In the event of a serious incident in relation to the use of the device, please inform the manufacturer (via your distributor) and the competent authority of the European Union member state where the incident occurred. For other jurisdictions, reporting must be made in accordance with regulatory requirements.

Reporting serious incidents helps provide more information about the safety of the diagnostic medical device.

### PROCEDURE

#### Quality control

Control sera with a known titer for Cholinesterase are commercially available for quality control, accompanied by certificates of analysis. Sclavo Diagnostics Normal and pathological control sera are available: Clinicontrol N 5x5 ml code B35181700 and Clinicontrol A 5x5 mL code B35181701. The values obtained must be contained within the acceptability range.

#### Calibration

For calibration use the "Calibrator serum Sclavo" code B35181702.

#### Traceability

The CHE-B concentration is reported in the package insert supplied with the "Calibrator Serum."

### SAMPLE

#### Type of sample and storage

Use serum or plasma containing heparin or EDTA. Pseudocholinesterase is stable in the serum for 1 week at 2-8°C and for at least 3 months at -20°.

### PREPARATION OF THE REAGENT

The reagents are liquid, ready to use. The solutions must be limpid with no evident precipitate. Pay attention to avoid bacterial contamination during use. The reagents are stable for 30 days if closed and stored at 2 - 8°C avoiding direct light. A slight variation in the colour, from batch to batch, does not affect the test results.

### ANALYTICAL TECHNIQUE

For automatic procedures, please refer to the user manual and application notes of the CHEMILAB analyzer. All applications not approved by Sclavo Diagnostics cannot be guaranteed in terms of performance and must therefore be evaluated by the user.

### Calculation of results

The results are automatically calculated by the analyzer using the calibration line. The analyzer automatically picks up the appropriate amount of a primary standard as set in the application method. The calibration line is obtained by interpolating the values obtained with an appropriate calculation algorithm.

### REFERENCE RANGE

Serum or plasma: 4700 – 14100 U/L

Each laboratory should calculate its own normal values on the basis of its local population.

### ANALYTICAL CHARACTERISTICS/PERFORMANCE

#### Linearity

Cholinesterase is linear up to a concentration of 15000 U/L. In the presence of higher concentrations, repeat the test by diluting the serum 1:10 in physiological saline and multiplying the final result by 10.

#### Recovery

Commercial control sera were analyzed with the kit in question following the guidelines of the CLSI protocol. The data obtained are shown in the following table.

Level	Replicates	Mean (U/L)	DS	CV%	Recovery
Low	5	4927	36,88	95,9	95,9%
High	5	5782	83,47	99,0	99%

#### Interference

Interference	Limits
Lipid	900 mg/dL
Bilirubin	55 mg/dL
Hemolysis	10 mg/dL

#### Precision of the method

Accuracy in the series (Within-run precision) – Repeatability				
Range	Replicates	Mean (U/L)	DS	CV%
Low	40	6161	68.6	1.11
High	40	7621	54.8	0.72
Total precision (Within-lab precision)				
Range	Replicates	Mean (U/L)	DS	CV%
Low	40	6162	117	1.91
High	40	7621	200	2.64



### Limit of Sensitivity








The limit of sensitivity was measured by analyzing scalar dilutions of a concentrated serum. Under the conditions established for this test the lowest detectable concentration is 212 U/L cholinesterase B

### Comparison between methods

The method for Cholinesterase B was compared with a similar commercially available method, analyzing 91 human samples. The correlation data between the two methods are reported in the table below.

Parameter	Estimation
Intercept	101
Slope	0,75
Correlation Coeff. (R)	0,99

### Symbols used in IFU and Packaging

 In vitro diagnostic medical device vitro	 Manufacturer
 Catalogue Number	 Instruction for use
 Lot Number	 Temperature limitation
 Expiration date	

### REFERENCES

1. **Koelle GB, Friedenwald JA** (1949) A histochemical method for localizing cholinesterase activity. *Proc Soc Exp Biol Med.*; 70(4):617-22
2. **Ellman GL, Courtney KD, Andres V jr, Feather-Stone RM** (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol*; 7: 88-95.
3. **Szasz G.** (1968) Serum Cholinesterase determination with acetyl- and butyrylthiocholine as substrate. *Clin Chim Acta*; 19: 191-204.
4. **Tabacco A, Moda E, Tarli P.** (1983) Poster "VIII Congresso Sibioc", Firenze.
5. **Weber H.** (1966) Quick and simple ultramicromethod for the determination of serum cholinesterase. *Dtsch Med Wochenschr*; 91:1927-1932.
6. **Clinical Laboratory Standards Institute (CLSI).** User Verification of Performance for Precision and Trueness; Approved Guideline – Second Edition. EP15-A2.
7. **Clinical Laboratory Standards Institute (CLSI).** Evaluation of Precision Performance of Quantitative Measurements Methods; Approved Guideline – Second Edition. EP05-A2.
8. **Clinical Laboratory Standards Institute (CLSI).** Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Third Edition. EP09-A3.
9. **Clinical Laboratory Standards Institute (CLSI).** Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, 2nd Edition – EP17
10. **Clinical Laboratory Standards Institute (CLSI).** Interference Testing in Clinical Chemistry, – Third Edition. - EP07.
11. **Clinical Laboratory Standards Institute (CLSI).** Evaluation of Linearity of Quantitative Measurement Procedures, 2nd Edition - EP06.

REVISION	DATE	CHANGE
Rev.A	01/2023	New Issue for IVDR Regulation (UE) 2017/746 compliance

